Valion Bio

Valion Bio (Nasdaq: VBIO), formerly Tivic Health Systems (Nasdaq: TIVC); renamed April 28, 2026 (SEC CIK 1787740). Late-stage biopharmaceutical company; lead program entolimod, a TLR5 agonist for acute radiation syndrome, licensed from Statera Biopharma in February 2025. Earlier: bioelectronic medicine, non-invasive nerve-stimulation devices.